| Non-decliners | Decliners | p-value | |
| Demographics | |||
| Subjects n | 17 | 8 | |
| Age yrs | 69 (53–78) | 72 (63–80) | 0.32 |
| Males/females n | 14/3 | 4/4 | 0.16 |
| Never-smokers | 6 (35) | 6 (75) | 0.10 |
| Lung function tests | |||
| FVC % pred | 70 (46–110) | 69 (44–114) | 0.60 |
| DL,CO % pred | 35 (17–92) | 29 (24–44) | 0.33 |
| Resting Pa,O2 mmHg | 77 (53–91) | 76 (61–101) | 0.77 |
| HRCT scores | |||
| Alveolar score | 1.25 (0.33–2.00) | 1.67 (1.00–2.17) | 0.053 |
| Interstitial score | 2.00 (1.00–3.00) | 2.08 (1.83–2.50) | 0.49 |
| Biomarkers | |||
| SP-D ng·mL−1 | 436 (110–1185) | 374 (250–836) | 0.74 |
| KL-6 U·mL−1 | 1895 (464–3857) | 1540 (687–2832) | 0.61 |
| CCL2 pg·mL−1 | 375 (152–1099) | 308 (144–1172) | 0.45 |
| CCL18 ng·mL−1 | 138 (64–395) | 118 (61–275) | 0.74 |
| Serum octreotide ng·mL−1 | 2.8 (<0.5–6.04) | 2.6 (<0.5–6.22) | 0.89 |
| Uptake of octreotide in the lungs | |||
| 111In-octreotide L/B | 5.32 (3.90–8.87) | 4.36 (3.49–5.81) | 0.11 |
Data are presented as mean (range) or n (%), unless otherwise stated. FVC: forced vital capacity; % pred: % predicted; DL,CO: diffusing capacity of the lung for carbon monoxide; Pa,O2: arterial oxygen tension; HRCT: high-resolution computed tomography; SP-D: surfactant protein-D; KL-6: Krebs von den Lungen-6; CCL: CC chemokine ligand; L/B: lung/background ratio. #: patients whose FVC decreased by ≥10% between two consecutive measurements (12-week interval) were termed as decliners and others as non-decliners.